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Transarterial chemoembolization (TACE) and yttrium 90 (90Y) transarterial radioembolization (TARE) are com-
monly used palliative treatments for patients with unre-
sectable hepatic malignancies. Infectious complications 
are rare after TACE, but their risk has been reported to be 
much greater in patients with biliary enteric anastomosis 
or stents and drains spanning across the ampulla of Vater 
(1,2). Infection risk has been shown to remain elevated de-
spite antibiotic prophylaxis (3). The purported mechanism 
for infection is ischemic injury of bile ducts colonized with 
enteric organisms (4).
Unlike TACE, which combines ischemia from emboli-
zation with local delivery of chemotherapeutic agents, the 
end point of TARE is delivery of a prescribed activity of 90Y 
microspheres without vascular stasis. The risk of hepatobi-
liary infection after TARE in the setting of an intact am-
pulla of Vater and no previous biliary intervention has been 
reported to be approximately 0%–2% (5–7). Data regard-
ing hepatobiliary infection risk after TARE in patients with 
a compromised ampulla of Vater or previous biliary tract 
intervention are limited to single-institution reports. These 
studies have not reported any instances of hepatobiliary in-
fection for patients with a history of biliary tract interven-
tion (8,9). Nevertheless, serious hepatobiliary infections in 
this patient population are known to occur. The purpose of 
our study was to determine the frequency of hepatobiliary 
infections after 90Y radioembolization in patients with liver 
malignancy and a history of biliary intervention.
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Purpose: To determine the frequency of hepatobiliary infections after transarterial radioembolization (TARE) with yttrium 90 (90Y) 
in patients with liver malignancy and a history of biliary intervention.
Materials and Methods: For this retrospective study, records of all consecutive patients with liver malignancy and history of biliary 
intervention treated with TARE at 14 centers between 2005 and 2015 were reviewed. Data regarding liver function, 90Y dosimetry, 
antibiotic prophylaxis, and bowel preparation prophylaxis were collected. Primary outcome was development of hepatobiliary 
infection.
Results: One hundred twenty-six patients (84 men, 42 women; mean age, 68.8 years) with primary (n = 39) or metastatic (n = 
87) liver malignancy and history of biliary intervention underwent 180 procedures with glass (92 procedures) or resin (88 proce-
dures) microspheres. Hepatobiliary infections (liver abscesses in nine patients, cholangitis in five patients) developed in 10 of the 
126 patients (7.9%) after 11 of the 180 procedures (6.1%; nine of those procedures were performed with glass microspheres). All 
patients required hospitalization (median stay, 12 days; range, 2–113 days). Ten patients required percutaneous abscess drainage, 
three patients underwent endoscopic stent placement and stone removal, and one patient needed insertion of percutaneous biliary 
drains. Infections resolved in five patients, four patients died (two from infection and two from cancer progression while infection 
was being treated), and one patient continued to receive suppressive antibiotics. Use of glass microspheres (P = .02), previous liver 
resection or ablation (P = .02), and younger age (P = .003) were independently predictive of higher infection risk.
Conclusion: Infectious complications such as liver abscess and cholangitis are uncommon but serious complications of transarterial 
radioembolization with 90Y in patients with liver malignancy and a history of biliary intervention.
© RSNA, 2018
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Devulapalli et al
Radiology: Volume 288: Number 3—September 2018  n  radiology.rsna.org 775
Materials and Methods
Our Health Insurance Portability and Accountability Act–
compliant retrospective multicenter study was approved by 
the institutional review boards of all participating institutions. 
The requirement to obtain informed consent was waived. 
Our study included all consecutive adult patients with a his-
tory of bile duct intervention who were subsequently treated 
with TARE at one of 14 participating medical centers in the 
United States and Canada between January 2005 and De-
cember 2015. None of the patients were excluded. TARE 
was performed by attending interventional radiologists (au-
thors N.F., M.C.S., M.S.J., G.E., C.N., K.F., R.P.L., R.C.G., 
D.B.B., S.W.K., S.C.R., D.M.L., S.B.W., and R.G., with 8, 
30, 28, 9, 20, 9, 5, 10, 18, 6, 27, 14, 7, and 8 years of experi-
ence, respectively) using glass (Therasphere; BTG, London, 
England) or resin (SIR-Sphere; Sirtex Medical, New South 
Wales, Australia) 90Y microspheres. The choice between glass 
and resin microspheres was made by the individual interven-
tional radiologists. This decision was uniform among individ-
ual patients (ie, the same agent was used when patients were 
treated more than once). Medical internal radiation dose and 
body surface area methodology were used for calculation of 
glass and resin microsphere activity, respectively.
A data collection spreadsheet template (Excel, version 
14.6.0; Microsoft, Redmond, Wash) was distributed to all 
authors at each participating center. Demographic data in-
cluded patient age at the time of the first TARE and sex. 
Collected clinical data included tumor type; type of previ-
ous bile duct intervention; information regarding history 
of liver resection, ablation, embolization, external beam ra-
diation, concurrent systemic chemotherapy, or biologic agent 
use; and Eastern Cooperative Oncology Group performance 
status. Laboratory parameters included preprocedure white 
blood cell count, platelet count, total serum bilirubin level, 
aspartate and alanine aminotransferase levels, alkaline phos-
phatase level, serum creatinine level, and international nor-
malized ratio for prothrombin time. Data regarding technical 
aspects of TARE included procedure date, type of 90Y carrier 
(glass or resin microspheres), extent of liver coverage dur-
ing TARE treatment (whole organ, lobar, other), estimated 
extent of liver parenchyma replacement by tumor (,25%, 
25%–50%, 51%–75%, .75%), volume of treated liver, de-
livered 90Y activity, and absorbed liver radiation dose. The 
data instrument also included information on periprocedural 
antibiotic and antiseptic bowel preparation use, including 
medications, doses, and duration of periprocedural therapy.
The primary outcome was development of hepatobiliary in-
fection, which was defined as liver abscess or cholangitis. For 
the subset of patients who developed hepatobiliary infection, 
collected information included type of infection (including 
pathogens if any were isolated), date of diagnosis, number and 
duration of hospitalizations and intensive care unit stays, and 
concomitant complications including septicemia, vasopressor 
medication use, renal failure, hemodialysis use, respiratory fail-
ure requiring intubation, and liver failure. Collected information 
regarding treatment of hepatobiliary infection included antibiot-
ics, duration of antibiotic therapy, number and types of invasive 
procedures (abscess drainage, endoscopic stent placement, per-
cutaneous transhepatic biliary drainage), and days with a per-
cutaneous drain or a biliary stent in situ. Outcome data for all 
infections categorized as infection resolution, ongoing treatment 
at the time of data censor date of March 31, 2017, and survival 
were also tabulated.
Descriptive statistics (eg, medians and percentages) were 
used to describe the patient characteristics and technical de-
tails. Univariable analysis of the primary dichotomous out-
come, presence of hepatobiliary infection, was performed by 
using generalized estimating equations with logit link function 
to account for patients who experienced multiple procedures 
(up to four procedures) clustered within one of 14 participat-
ing centers. The univariable predictors with P , .20 were then 
assessed in a bivariate generalized estimating equation model 
with two variables that included 90Y agent. Six bivariate mod-
els were assessed for (a) age and 90Y agent, (b) neuroendocrine 
tumor and 90Y agent, (c) previous resection and 90Y agent, (d) 
international normalized ratio for prothrombin time and 90Y 
agent, (e) delivered activity and 90Y agent, and (f ) greater than 
25% liver replacement with tumor and 90Y agent. Variables 
were included in the final multivariable generalized estimat-
ing equation analysis if their P values were less than .05 in the 
bivariate model. The final multivariable model included age (in 
years), previous liver resection or ablation, and 90Y agent. 90Y 
agent was planned a priori to be included in the final model 
regardless of statistical significance at P , .05 in the bivariate 
analysis. The multivariable model included 11 infection events. 
We relaxed the rule of 10 events per variable (10) by includ-
ing three variables in the final model (ie, age, previous resec-
tion, and glass microspheres). We compared this multivariable 
model to the other models, bivariable and univariable models, 
to assess whether the magnitude of the results, confidence in-
tervals (CIs), and/or P values changed. We found the results 
Abbreviations
CI = confidence interval, HR = hazard ratio, TACE = transarterial che-
moembolization, TARE = transarterial radioembolization
Summary
In patients with a liver malignancy and a history of biliary intervention 
who undergo transarterial radioembolization with 90Y microspheres, in-
fectious complications and morbidities such as liver abscess and cholan-
gitis occur but are uncommon.
Implications for Patient Care
 n In patients with liver malignancy and prior biliary intervention, 
transarterial radioembolization (TARE) with yttrium 90 (90Y) 
may be a safer local-regional treatment alternative with respect 
to hepatobiliary infection risk when compared with transarterial 
chemoembolization.
 n For patients with previous biliary tract interventions, the relative 
risks and benefits of TARE with 90Y should be carefully weighed, 
as infections tend to result in substantial clinical sequelae.
 n Radioembolization with 90Y resin microspheres may result in a 
lower risk of hepatobiliary infection compared with 90Y glass mi-
crospheres.
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were similar and remained statistically significant regardless of 
the results reported by the model (ie, univariable, bivariable, 
or multivariable). The magnitude of the association between 
the outcome and each variable was reported as the hazard ra-
tio (HR) with associated 95% CIs. Two-sided P values were 
reported, and P , .05 was considered indicative of a statisti-
cally significant difference in the final model. Owing to the 
low number of events, interaction terms between 90Y agent and 
each of the variables were not considered and a forward step-
wise approach to analysis was undertaken. Statistical analyses 
were performed by author A.A.L. by using software (SAS, v. 
9.4; SAS, Cary, NC).
Results
Patient Characteristics
A total of 126 patients (mean age, 68.8 years; age range, 30–89 
years; 84 men) who underwent 180 TARE procedures after 
biliary tract intervention were included in our study. Baseline 
demographic, clinical, and laboratory parameters are sum-
marized in Table 1. TARE procedures were performed for the 
treatment of a primary liver malignancy in 39 patients (18 pa-
tients with hepatocellular carcinoma and 21 with cholangiocar-
cinoma), whereas 87 of the 126 patients (69%) were treated for 
metastatic disease to the liver. The extent of liver parenchyma 
replacement by tumor was less than 25% or 25%–50% before 
most TARE procedures (38% and 36%, respectively). None of 
the patients had a history of liver transplantation or neutropenia 
or were known to be immunocompromised. The mean duration 
of follow-up was 10.9 months (range, 0.3–52.5 months).
Infectious Complications
Eleven of the 180 procedures (6.1%) resulted in hepatobiliary 
infections in 10 of the 126 patients (7.9%). Six patients had 
liver abscesses (Figs 1, 2), three with liver abscess and cholangi-
tis and two with cholangitis. The median time between TARE 
and diagnosis of infection was 46 days (range, 3–132 days). 
Nine of the procedures used 90Y glass microspheres.
Antibiotic prophylaxis was used before nine of the 11 TARE 
procedures that resulted in infection (82%). Ten of the 11 hep-
atobiliary infections (91%) necessitated treatment in the inpa-
tient setting. One patient with cholangiocarcinoma who had 
an indwelling endoscopic biliary stent was successfully treated 
for cholangitis as an outpatient 18 days after TARE to two 
Table 1: Patient Characteristics
Variable Value
Median age (y)* 64 (30–89)
Sex
 M 84 (67)
 F 42 (33)
Primary liver tumor
 Hepatocellular carcinoma 18 (14)
 Cholangiocarcinoma 21 (17)
Metastatic disease 87 (69)
 Adenocarcinoma 42 (33)
 Neuroendocrine tumors 40 (32)
 Sarcoma 3 (2.4)
 Squamous cell carcinoma 1 (0.8)
 Pseudopapillary tumor of pancreas 1 (0.8)
Liver parenchyma replacement
 ,25% 68 (38)
 25%–50% 64 (36)
 51%–75% 14 (7.8)
 .75% 5 (2.8)
 Not specified 29 (16)
Biliary intervention
 Biliary-enteric anastomosis 64 (51)
 Indwelling biliary stent
  Metal 19 (15)
  Plastic 19 (15)
 Sphincterotomy (no stent) 16 (13)
 Internal-external biliary drain 5 (4.0)
 Not specified 3 (2.4)
Concurrent systemic chemotherapy
 Yes 25 (14)
 No 134 (74)
 Not specified 21 (12)
Prior liver radiation therapy
 Yes 8 (6.3)
 No 118 (94)
Prior liver resection or ablation
 Yes 41 (33)
 No 85 (67)
Prior chemoembolization or bland  
  embolization
 Yes 21 (17)
 No 105 (83)
ECOG performance status
 0 97 (54)
 1 52 (29)
 2 3 (1.7)
 3 2 (1.1)
 Not specified 26 (14)
Median baseline laboratory values*
 White blood cell count (103/mL) 6.1 (2.2–15.2)
 Total bilirubin level (mg/dL) 0.87 (0.2–8.0)
 Alkaline phosphatase level (U/L) 169 (55–2127)
 Aspartate aminotransferase level (U/L) 37 (11–148)
 Alanine aminotransferase level (U/L) 32 (10–147)
Table 1 (continues)
Table 1 (continued): Patient Characteristics
Variable Value
 International normalized ratio for  
  prothrombin time
1.1 (0.8–2.4)
 Platelet count (103/mL) 206 (33–484)
 Creatinine level (mg/dL) 0.94 (0.4–6.4)
Note.—Except where indicated, data are numbers of patients or 
procedures, with percentages in parentheses. ECOG = Eastern 
Cooperative Oncology Group.
* Numbers in parentheses are the range.
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be performed. The second patient with hepatocellular carci-
noma and previously placed endoscopic biliary stent developed 
liver abscess and cholangitis 74 days after TARE with glass 
microspheres. The patient was hospitalized for 12 days, under-
went exchange of the endoscopic biliary stent, and completed 
a 14-day course of intravenous vancomycin and ceftazidime. 
However, 9 days after completing the course of antibiotics, the 
patient died of sepsis attributed to a hepatobiliary source. The 
two deaths occurred in patients who did not receive antibiotic 
prophylaxis or bowel preparation before TARE.
Technical Details of TARE
Glass 90Y microspheres were used in 92 of the 180 TARE pro-
cedures (51.1%) performed in 61 of the 126 patients (48.4%), 
whereas resin 90Y microspheres were used in 88 procedures 
(48.9%) performed in 65 patients (51.6%). None of the pa-
tients were treated with both agents. Seventy-nine patients 
liver segments with 90Y glass microspheres. The same patient 
developed cholangitis and liver abscess 33 days after the second 
TARE procedure performed with glass microspheres and tar-
geting one liver segment.
The clinical course and outcomes of patients with infectious 
complications are outlined in Table 2. Infections resolved in 
five patients. Two patients died of cancer progression while re-
ceiving antibiotics and with drainage catheters in place. One 
patient continued to receive rotating suppressive antibiotic 
treatment (amoxicillin and clavulinate and trimethoprim-sul-
famethoxasole) 27 months after the diagnosis of a liver abscess 
(based on data censor date of March 31, 2017). Hepatobiliary 
infections resulted in two deaths. One patient with pancreatic 
neuroendocrine tumor and history of biliary-enteric anasto-
mosis developed a liver abscess 30 days after TARE with resin 
microspheres. One day after presenting with infectious symp-
toms, the patient died of sepsis, before abscess drainage could 
Figure 1: Images in 52-year-old man who underwent Whipple procedure for resection of 
pancreatic neuroendocrine tumor. (a) Gadolinium-enhanced spoiled gradient-echo MR image 
shows progressive bilobar liver metastases. (b) Digital subtraction angiogram from proper he-
patic artery helps confirm presence of multiple hypervascular masses. Four weeks after second 
yttrium 90 (90Y) radioembolization with glass microspheres, patient developed abdominal pain 
and nausea. (c) Contrast-enhanced CT scan demonstrates elongated region of hypoattenuation 
in caudate lobe (arrow) and foci of gas within nondilated intrahepatic bile ducts (arrowhead). 
Despite 1-month course of broad-spectrum antibiotics, patient developed recurrent sepsis. (d) 
Repeat CT scan demonstrates gas- and fluid-containing abscess (arrow) in caudate lobe. (e) 
Abscess was drained percutaneously under CT guidance. (f) Plain abdominal radiograph ob-
tained after tube injection with iodinated contrast material 3 weeks after drainage demonstrates 
small residual cavity and communication to biliary tree (arrows). Two weeks later, patient was 
feeling well and reported minimal drainage from catheter. (g) Plain abdominal radiograph 
obtained after iodinated contrast material injection demonstrates small residual cavity and 
resolution of biliary fistula. Drain was removed, and abscess did not recur during 2.5 years of 
follow-up.
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were treated once (40 with glass microspheres, 39 with resin 
microspheres), 41 patients were treated twice (19 with glass 
microspheres, 22 with resin microspheres), five patients were 
treated three times (two with glass microspheres, three with 
resin microspheres), and one patient was treated four times with 
resin microspheres. For patients who underwent more than 
one radioembolization procedure, the average time between 
the procedures was 2.5 months (range, 0.7–12.3 months). 
For five procedures, the previously treated vascular territory 
was targeted. For the remaining 49 procedures, a different 
territory was treated. Median delivered activity was 2.36 GBq 
for glass microspheres and 1.04 GBq for resin microspheres 
(Table 3). The corresponding median absorbed liver doses 
were 116 Gy and 73 Gy for glass and resin microspheres, 
respectively. 90Y microsphere administrations were to the en-
tire liver for 21 of the 180 procedures (11.7%), were to the 
right or left lobe for 125 (69.4%), and targeted one to three 
segments for 30 (16.1%) (Table 3). The median targeted liver 
parenchyma volumes for whole liver, right lobe, and left lobe 
treatments were 1565 mL, 1115 mL, and 620 mL, respec-
tively (Table 3).
Antibiotic Regimens
Selection of the preprocedure antibiotic prophylaxis and post-
procedure therapy was at the discretion of the physicians at 
each of the participating clinical sites. Antibiotics were used 
for 151 of the 180 TARE procedures (85.8%) involving 106 
patients. Antibiotics were started at least 1 day before TARE 
for 135 of the 180 procedures (75%) (Table E1 [online]). The 
median duration of preprocedure antibiotic therapy was 2 days 
(range, 1–14 days). Most patients (62%) were treated for 2–5 
days before radioembolization. The most commonly used anti-
biotics were a combination of levofloxacin and metronidazole 
(62 procedures, 46%), single-agent moxifloxacin (35 proce-
dures, 26%), and a combination of ciprofloxacin and metroni-
dazole (nine procedures, 6.7%).
Postprocedure antibiotics were administered after 143 of 
the 180 TARE procedures (79%) (Table E2 [online]). The 
median duration of postprocedure antibiotic therapy was 14 
days (range, 3–30 days). Most patients (58%) were treated for 
8–14 days. The most commonly used antibiotic regimens in 
the postprocedure period were levofloxacin with metronidazole 
(61 procedures, 43%), single-agent moxifloxacin (36 proce-
dures, 25%), single-agent ciprofloxacin (16 procedures, 11%), 
ciprofloxacin with metronidazole (nine procedures, 6.3%), 
single-agent levofloxacin (six procedures, 4.2%), and amoxicil-
lin clavulinate (four procedures, 2.8%).
Antiseptic Bowel Preparation
Selection of bowel preparation regimens was at the discretion of 
the physicians at each of the participating clinical sites. A bowel 
preparation regimen was used before 48 of the 180 TARE pro-
cedures (27%) (Table E3 [online]). The most common regimens 
were neomycin with erythromycin (33 procedures, 69%) and 
polyethylene glycol with bisacodyl (nine procedures, 19%).
Predictors Associated with Risk of Infection
Univariable generalized estimating equation analysis demon-
strated that younger age at the time of TARE, lower international 
normalized ratio for prothrombin time, higher delivered 90Y ac-
tivity, use of glass microspheres, and history of liver resection or 
ablation were associated with the development of hepatobiliary 
infection after TARE (Table 4). Risk of infection was indepen-
dent of the number of TARE procedures performed for a given 
patient. Bivariate analyses of infection showed an association 
(P , .05) of 90Y glass microsphere agent with previous liver 
resection or ablation (HR = 7.28; 95% CI = 1.79, 29.56; P = 
.006) and with younger age at the time of TARE (HR = 0.92; 
Figure 2: Images in 48-year-old woman who underwent right hepatectomy for multifocal well-differentiated metastatic pancreatic neuroendo-
crine tumor to liver. The clinical course was complicated by common hepatic duct stricture, which was treated with sphincterotomy and endoscopic 
stent placement. (a) Contrast-enhanced MR image shows that patient subsequently developed multiple metastases in left liver lobe remnant (arrow). 
Left liver lobe yttrium 90 radioembolization with resin microspheres was performed. (b) CT scan obtained for work-up of fever and abdominal 
pain 105 days after radioembolization reveals a fluid collection (arrowhead) in hepatic segment 4A. An endoscopic stent was in place (arrow). 
Abscess was treated with US-guided aspiration and a prolonged course of antibiotics, which included imipenem and linezolid for extended spec-
trum beta-lactamase–producing Escherichia coli and vancomycin-resistant Enterococcus faecium species.
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biliary intervention after TARE. Cholapranee et al (8) reported 
no infectious complications in a cohort of 16 patients under-
going 24 90Y resin microsphere TARE procedures. This subset 
of patients was included in our study. All patients in that study 
received a prophylactic regimen consisting of oral levofloxacin 
and metronidazole 2 days before the procedure and continuing 
for 14 days after, oral neomycin-erythromycin bowel prepara-
tion the day before, and intravenous levofloxacin-metronidazole 
95% CI = 0.87, 0.97; P = .003). Mul-
tivariable analysis showed that use of 
glass microspheres (HR = 6.90; 95% 
CI = 1.40, 35.10; P = .02), previ-
ous liver resection or ablation (HR = 
6.10; 95% CI = 1.30, 27.60; P = .02), 
and younger age per year (HR= 0.92; 
95% CI = 0.88,0.97; P = .003) were 
associated with greater risk of devel-
oping hepatobiliary infection after 
TARE.
Discussion
Our study demonstrated a 
7.9% frequency of liver abscess 
and/or cholangitis after TARE in pa-
tients with a history of biliary in-
tervention. The rate of infection in 
our cohort was greater than the hep-
atobiliary infection rates of 0%–2% 
reported in patients with an intact 
ampulla of Vater who had undergone 
TARE (5–7). For example, the larg-
est published series of biliary sequelae 
after TARE in 327 patients with no 
prior biliary intervention demon-
strated three suspected infections 
(1.0% complication rate from infec-
tion) (5).
Overall, the frequency of hepatobi-
liary infection in our study was much 
lower than that reported for patients 
with a history of biliary intervention 
treated with TACE. For example, Woo 
et al (11) reported that 12 of 25 pa-
tients (48%) with biliary enteric anas-
tomosis developed a liver abscess after 
TACE. Kim et al (2) reported that six 
of seven patients (86%) with a history 
of Whipple procedure developed liver 
abscesses after TACE. High rates of in-
fection after TACE in patients with bili-
ary enteric anastomosis have also been 
noted despite aggressive antibiotic pro-
phylaxis. Cholapranee et al (8) reported 
that three of 13 patients (23%) devel-
oped liver abscesses after TACE despite 
2 weeks of levofloxacin and metronida-
zole beginning 2 days before the proce-
dure. Patel et al (3) reported that two of seven patients (28.6%) 
developed liver abscesses after chemoembolization despite a simi-
lar regimen of levofloxacin and metronidazole. Khan et al (12), 
however, found no infections among 10 patients undergoing 25 
TACE procedures who were treated with moxifloxacin starting 3 
days before their procedure and continuing for 17 days thereafter.
Two single-institution studies have investigated the rates of 
hepatobiliary infection after TARE in patients with a history of 
Table 2: Treatment Summary for Patients with Infectious Complications
Parameter Value
Primary tumor site
 Pancreatic neuroendocrine tumor 6
 Cholangiocarcinoma 2
 Hepatocellular carcinoma 1
 Leiomyosarcoma 1
Hospitalizations
 Median hospital admissions per patient 1 (1–7)
 Median cumulative days in the hospital 12 (2–113)
ICU stays
 No. of patients admitted to ICU 4
 Median ICU admissions per patient 1 (1–3)
 Median cumulative days in the ICU 3 (2–31)
Complication specifics
 Septicemia 8
 Vasopressor requirement 3
 Acute kidney injury 3
 Hemodialysis 1
 Mechanical ventilation 0
 Liver failure 2
Microbiology
 Actinobacter 1
 Bacteroides fragilis 1
 Candida species 3
 Clostridium species 2
 Enterobacter species 1
 Enterococcus species 5
 Escherichia coli 3
 Klebsiella species 2
 Pseudomonas aeruginosa 2
 Raoultella ornithinolytica 1
 Streptococus species 3
Invasive procedures
 No. of patients needing an invasive procedure 9
 Median no. of invasive procedures per patient 1 (1–8)
 No. of patients needing imaging-guided abscess aspiration 4
 Median no. of imaging-guided abscess aspirations per patient 1 (1–3)
 No. of patients needing imaging-guided abscess drain insertion 5
 Median no. of imaging-guided abscess drain insertions per patient 2 (1–3)
 No. of patients needing PTBD 1
 No. of PTBD procedures per patient 2
 No. of patients needing ERCP with stent exchange 3
 No. of ERCP procedures per patient 1
Note.—Except where indicated, data are numbers of patients. Numbers in parentheses are 
the range. ERCP = endoscopic retrograde cholangiopancreatography, ICU = intensive care 
unit, PTBD = percutaneous transhepatic biliary drain.
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on the day of treatment. Gie-
sel et al (9) also demonstrated 
no infectious complications in 
their cohort of nine patients. 
These patients were also treated 
with resin microspheres but 
did not undergo preprocedural 
bowel preparation or antibiotic 
prophylaxis.
The clinical course of the 
patients who developed chol-
angitis and/or liver abscess was 
complex. All patients required 
at least one hospitalization, four 
patients needed intensive care 
unit level of care, and two pa-
tients died as a result of the 
infections. Furthermore, pre-
procedural bowel preparation 
or administration of antibiotic 
prophylaxis were not found 
to be associated with a lower 
risk of infection, unlike reduc-
tions seen in similar groups of 
patients who were treated with 
TACE (3,8,12). Despite this, 
the two deaths in our cohort oc-
curred in patients who did not 
receive bowel preparation or an-
tibiotic prophylaxis.
In our study, the use of 90Y 
glass microspheres was associ-
ated with a 6.9 times higher odds of hepatobiliary infection 
compared with the use of 90Y resin microspheres. This differ-
ence may be related to the typically higher radiation doses de-
livered during TARE with glass microspheres (due to difference 
in radiation dosimetry models used for resin and glass micro-
spheres) as well as due to higher activity carried by the individ-
ual 90Y glass microsphere particles. At the time of calibration, 
the average individual activity of 90Y glass microspheres is 2500 
Bq, 50-fold higher than the average individual activity of 90Y 
resin microspheres (50 Bq) (13). Furthermore, glass micro-
spheres are smaller in diameter compared with resin micro-
spheres, which may result in more distal deposition of glass 
microspheres and, therefore, in a greater ischemic potential. 
Deposition of microspheres with higher activity and smaller 
Table 3: Microsphere Composition, Delivered Activity, and Treated Liver Volume
Variable No. of Procedures* Median Target Volume (mL)† Median Activity (GBq)† Median Absorbed Liver Dose (Gy)†
90Y microspheres
 Glass 92 (51.1) 977 (30–3127) 2.36 (0.13–6.01) 116 (57–203)
 Resin 88 (48.9) 662 (256–1430) 1.04 (0.34–2.02) 73 (19–207)
90Y distribution
 Whole liver 21 (11.7) 1565 (1094–3127) 2.76 (1.30–5.85) 65 (59–71)
 Right lobe 80 (44.4) 1115 (300–2600) 1.83 (0.60–4.67) 110 (49–157)
 Left lobe 45 (25.0) 620 (120–1982) 0.95 (0.34–2.73) 103 (19–170)
 One segment 10 (5.6) 177 (30–880) 0.76 (0.13–1.51) 131 (51–196)
 Two segments 17 (9.4) 488 (132–1735) 1.35 (0.40–4.50) 135 (106–203)
 Three segments 2 (1.1) 256, 2200 1.10, 6.01 207, 124
Note.—90Y = yttrium 90.
* Numbers in parentheses are percentages.
† Numbers in parentheses are the range.
Table 4: Results of the Univariable Analyses
Variable HR P Value
Demographic characteristics
 Age 0.93 (0.88, 0.97) .001
 Female sex 1.75 (0.47, 6.52) .40
Clinical parameters
 Biliary-enteric anastomosis 2.00 (0.48, 8.37) .34
 Neuroendocrine tumor 2.66 (0.69, 10.17) .15
 ECOG performance status .0 0.60 (0.15, 2.39) .47
 .25% liver replaced with tumor 0.40 (0.10, 1.59) .20
 Concurrent chemotherapy 0.59 (0.078, 4.43) .60
 Prior resection 6.90 (1.69, 28.13) .007
Laboratory parameters
 Total bilirubin level 0.69 (0.15, 3.18) .63
 Aspartate aminotransferase level 1.00 (0.95, 1.04) .86
 Alanine aminotransferase level 1.00 (0.96, 1.03) .87
 Alkaline phosphatase level 1.00 (0.99, 1.00) .24
 White blood cell count 1.06 (0.87, 1.28) .55
 Platelet count 1.00 (0.99, 1.00) .49
 International normalized ratio for prothrombin time 0.0006 (0.0001, 0.46) .03
 Creatinine level 0.98 (0.96, 1.01) .26
Technical parameters
 Glass microspheres 5.73 (1.17, 28.13) .03
 Delivered activity 1.37 (1.04, 1.80) .02
 Absorbed dose 0.99 (0.98, 1.01) .64
 Whole liver treatment 0.70 (0.092, 5.86) .77
 Antibiotic prophylaxis 1.50 (0.28, 8.02) .63
 Bowel preparation 0.704 (0.088, 6.34) .79
Note.—Numbers in parentheses are 95% confidence intervals. ECOG = Eastern Cooperative 
Oncology Group, HR = hazard ratio.
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size in the vicinity of bile ducts may make biliary epithelium 
more susceptible to necrosis, thus predisposing patients to 
translocation of bacteria from the colonized biliary tract into 
the liver parenchyma and into the bloodstream.
Our study has several limitations. First, this was a retrospec-
tive study, and the reported data were limited to the information 
contained in the medical records obtained as a part of routine 
medical care. Second, due to the multisite nature of our study, 
the clinical approaches to TARE with respect to volume of target 
liver tissue, choice of radioembolization agent, and dosimetry 
were specific to the investigator. Third, the antibiotic prophylaxis 
and bowel preparation regimens varied widely between the indi-
vidual institutions. Fourth, despite the large sample size, the low 
rate of infectious complications and heterogeneity of antibiotic 
prophylaxis and bowel preparation regimens may have limited 
statistical assessment of the protective role of antibiotic prophy-
laxis and bowel preparation before TARE.
In patients with a liver malignancy and a history of biliary 
intervention who undergo TARE with 90Y microspheres, infec-
tious complications and morbidities such as liver abscess and 
cholangitis occur but are uncommon. Therefore, the relative 
risks and benefits of TARE for patients with previous biliary 
tract interventions should be carefully weighed before proceed-
ing with TARE treatment. Further multicenter prospective eval-
uation with a larger cohort is required to make recommenda-
tions regarding an optimal periprocedure antibiotic regimen and 
the potential role of preprocedure bowel preparation.
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